+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cephalosporin Drugs Market by Drug Class, Route Of Administration, End User, Distribution Channel, Dosage Form, Application - Global Forecast to 2030- Product Image
Cephalosporin Drugs Market by Drug Class, Route Of Administration, End User, Distribution Channel, Dosage Form, Application - Global Forecast to 2030- Product Image
Sale

Cephalosporin Drugs Market by Drug Class, Route Of Administration, End User, Distribution Channel, Dosage Form, Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011269
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cephalosporin Drugs Market grew from USD 12.11 billion in 2024 to USD 12.95 billion in 2025. It is expected to continue growing at a CAGR of 6.68%, reaching USD 17.87 billion by 2030.

Understanding the Role of Cephalosporin Drugs in Modern Healthcare

Cephalosporin drugs have long been a cornerstone of antimicrobial therapy, offering a broad spectrum of activity against diverse bacterial pathogens. Originating from natural fungal metabolites, modern cephalosporins have evolved through multiple generations to address shifting resistance patterns and clinical needs. Their versatility and efficacy make them indispensable in hospital settings, outpatient clinics, and homecare environments alike.

In recent years, advances in medicinal chemistry and pharmacokinetics have driven the development of fifth-generation cephalosporins, further expanding treatment options for resistant infections. At the same time, ongoing challenges such as antimicrobial stewardship, pricing pressures, and supply chain vulnerabilities continue to shape market dynamics. This executive summary provides a concise yet comprehensive overview of the factors driving growth, the emerging challenges poised to redefine the landscape, and the strategic imperatives for stakeholders across the healthcare spectrum.

Landmark Innovations and Digital Integration Reshaping Market Dynamics

The cephalosporin market is undergoing transformative shifts driven by evolving resistance mechanisms and a renewed emphasis on innovation. Breakthroughs in molecular engineering have yielded novel compounds exhibiting potent activity against multidrug-resistant strains, while real-time data analytics are optimizing drug development pathways and clinical trials. Moreover, regulatory bodies are streamlining approval processes for agents addressing critical unmet needs, accelerating the transition from discovery to commercial availability.

Concurrently, digital health platforms are reshaping prescribing practices and patient adherence monitoring. These technologies enable clinicians to make data-driven decisions on optimal dosing regimens and therapeutic combinations, reducing adverse events and improving outcomes. As hospitals and clinics adopt value-based care models, the focus on cost-effective, evidence-backed therapies positions advanced cephalosporins as key contributors to both clinical excellence and financial performance.

Navigating the Ripple Effects of New U.S. Tariffs on Antibiotic Supply Chains

In 2025, the United States implemented new tariffs targeting critical active pharmaceutical ingredients and finished antibiotic products, triggering significant reverberations throughout the cephalosporin supply chain. Manufacturers faced increased input costs for imported raw materials, particularly those sourced from major producing nations. These elevated costs have been partially absorbed by producers, while some have been passed on to healthcare providers, impacting formularies and budget allocations.

The tariff-driven price adjustments have prompted companies to reevaluate procurement strategies, enhance domestic manufacturing capabilities, and explore alternative sourcing partnerships. While short-term margins experienced compression, the long-term outcome has been a heightened focus on supply chain resilience. Investments in nearshoring, strategic inventory management, and collaborative agreements with local suppliers are mitigating future exposure to sudden policy shifts.

Deep-Dive into Market Segmentation Drivers and Patient Pathways

The cephalosporin market exhibits distinct dynamics when analyzed by drug class, route of administration, end user, distribution channel, dosage form, and application. Fifth-generation molecules command premium positioning due to their efficacy against resistant pathogens, while first-generation compounds remain vital for common Gram-positive infections. Fourth- and second-generation drugs offer balanced coverage in both inpatient and outpatient settings, and third-generation variants such as cefdinir, cefixime, cefotaxime, ceftazidime, and ceftriaxone dominate key therapeutic protocols.

Intravenous administration retains prominence in acute care hospitals for severe infections, yet the growth of oral formulations is fueling outpatient and home infusion services. Ambulatory surgical centers and clinics increasingly leverage convenient oral options for prophylactic and therapeutic use, complementing hospital stewardship programs. Distribution pathways reflect diverse stakeholder preferences, with hospital pharmacies managing bulk injectable inventories, retail pharmacies meeting community demand, and online pharmacies emerging as a critical access point for home-based therapies.

Capsules and tablets offer patient-friendly dosing schedules, while injections and powders maintain the gold standard for high-bioavailability intravenous therapy. Clinicians deploy cephalosporins across a wide spectrum of applications, from treating gonorrhea to managing respiratory tract infections including bronchitis and pneumonia, combating sepsis in intensive care units, addressing skin and soft tissue infections, and resolving urinary tract infections. This multifaceted segmentation underscores the necessity for tailored strategies across product portfolios and care settings.

Regional Growth Patterns and Strategic Market Positioning

Geographically, the Americas lead with robust healthcare infrastructure, widespread insurance coverage, and significant investments in antimicrobial stewardship programs. Demand for advanced cephalosporins is driven by elevated incidence of hospital-acquired infections and an aging population requiring prophylactic interventions.

In Europe, the Middle East, and Africa, diverse regulatory frameworks influence market entry timelines and pricing strategies. Western Europe shows strong uptake of premium agents backed by national formularies, whereas emerging markets in the Gulf region and Sub-Saharan Africa are focused on expanding basic access and overcoming distribution challenges.

Asia-Pacific exhibits the fastest growth trajectory, propelled by expanding hospital networks in China and India, rising prevalence of resistant pathogens, and increasing government funding for pharmaceutical R&D. Government incentives and public-private partnerships are accelerating capacity building for local manufacturing, positioning the region as both a key consumption hub and a growing export base.

Competitive Dynamics Among Innovators, Generics, and Specialty Firms

Leading pharmaceutical innovators and established generic producers alike are shaping the competitive landscape. Some global players are leveraging deep research pipelines to introduce novel cephalosporin derivatives with differentiated safety and efficacy profiles. Others are intensifying collaborations with biotech firms to license targeted molecules or co-develop combination therapies addressing resistant strains.

Generic and biosimilar manufacturers are expanding capacity to meet rising demand for cost-effective antibiotics in both established and emerging markets. Strategic alliances with contract manufacturing organizations are enabling scalable production and geographic diversification. Meanwhile, specialty pharmaceutical companies are carving out niches by focusing on novel delivery systems, patient support programs, and value-based contracting with healthcare payers.

Strategic Initiatives to Advance Market Leadership and Growth

To capitalize on evolving market conditions, industry leaders must accelerate investment in next-generation cephalosporins that address critical resistance gaps. Strengthening ties with regulatory agencies and participating in adaptive trial designs will expedite approvals and market access. Enhancing digital engagement through real-world evidence platforms can demonstrate value to payers and support premium positioning.

Supply chain resilience should be bolstered through strategic sourcing agreements, nearshore manufacturing, and advanced analytics for demand forecasting. Tailored commercialization strategies are essential, aligning intravenous portfolios with acute care stakeholders while championing oral formulations for outpatient settings. Finally, integrating antimicrobial stewardship initiatives within marketing and educational programs will foster long-term adoption and sustainable use.

Robust Methodology Ensuring Depth, Accuracy, and Reliability

This analysis is grounded in a rigorous two-tiered research methodology combining primary interviews with key opinion leaders, procurement specialists, regulatory experts, and senior executives across pharmaceutical companies. Secondary research sources included peer-reviewed journals, regulatory filings, corporate financial reports, and proprietary databases tracking drug approvals and patent expirations.

Data was triangulated and validated through in-depth quantitative modeling, ensuring consistency across segment definitions and regional parameters. A focused advisory council guided the refinement of market segments and critical application areas. Quality control procedures encompassed thorough editorial review, cross-referencing with industry benchmarks, and iterative feedback loops with subject matter experts.

Synthesizing Key Learnings to Chart Future Milestones

The cephalosporin drugs market stands at a pivotal juncture, shaped by advanced molecular innovations, shifting regulatory frameworks, and the imperative of antimicrobial stewardship. Supply chain realignments in response to new tariffs have underscored the need for resilience and agility. Detailed segmentation analysis reveals diverse opportunities across drug classes, administration routes, care settings, and therapeutic applications.

Regional insights highlight the Americas’ established leadership, EMEA’s nuanced regulatory landscape, and Asia-Pacific’s rapid expansion. Competitive forces among innovators, generics, and specialty firms will continue to drive portfolio diversification and strategic collaborations. By embracing forward-looking recommendations and leveraging rigorous research foundations, stakeholders can navigate complexities and secure sustainable growth in this essential therapeutic arena.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Fifth Generation
    • First Generation
    • Fourth Generation
    • Second Generation
    • Third Generation
      • Cefdinir
      • Cefixime
      • Cefotaxime
      • Ceftazidime
      • Ceftriaxone
  • Route Of Administration
    • Intravenous
    • Oral
  • End User
    • Ambulatory Surgical Centers
    • Clinics
    • Homecare
    • Hospitals
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Dosage Form
    • Capsule
    • Injection
    • Powder
    • Tablet
  • Application
    • Gonorrhea
    • Respiratory Tract Infections
      • Bronchitis
      • Pneumonia
    • Sepsis
    • Skin Infections
    • Urinary Tract Infections
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Viatris Inc.
  • Dr. Reddy’s Laboratories Ltd
  • Sun Pharmaceutical Industries Ltd
  • Lupin Limited
  • Cipla Limited
  • Sanofi S.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cephalosporin Drugs Market, by Drug Class
8.1. Introduction
8.2. Fifth Generation
8.3. First Generation
8.4. Fourth Generation
8.5. Second Generation
8.6. Third Generation
8.6.1. Cefdinir
8.6.2. Cefixime
8.6.3. Cefotaxime
8.6.4. Ceftazidime
8.6.5. Ceftriaxone
9. Cephalosporin Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
10. Cephalosporin Drugs Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Clinics
10.4. Homecare
10.5. Hospitals
11. Cephalosporin Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Cephalosporin Drugs Market, by Dosage Form
12.1. Introduction
12.2. Capsule
12.3. Injection
12.4. Powder
12.5. Tablet
13. Cephalosporin Drugs Market, by Application
13.1. Introduction
13.2. Gonorrhea
13.3. Respiratory Tract Infections
13.3.1. Bronchitis
13.3.2. Pneumonia
13.4. Sepsis
13.5. Skin Infections
13.6. Urinary Tract Infections
14. Americas Cephalosporin Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Cephalosporin Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Cephalosporin Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. F. Hoffmann-La Roche Ltd
17.3.3. Teva Pharmaceutical Industries Ltd
17.3.4. Sandoz International GmbH
17.3.5. Viatris Inc.
17.3.6. Dr. Reddy’s Laboratories Ltd
17.3.7. Sun Pharmaceutical Industries Ltd
17.3.8. Lupin Limited
17.3.9. Cipla Limited
17.3.10. Sanofi S.A.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. CEPHALOSPORIN DRUGS MARKET MULTI-CURRENCY
FIGURE 2. CEPHALOSPORIN DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. CEPHALOSPORIN DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. CEPHALOSPORIN DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. CEPHALOSPORIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CEPHALOSPORIN DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFDINIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFIXIME, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFOTAXIME, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTAZIDIME, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SEPSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 64. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 68. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 70. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 76. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 111. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 113. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 117. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 119. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 120. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 125. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 135. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 137. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 141. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 143. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 145. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 149. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 175. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 177. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 181. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 182. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 189. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 191. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 193. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 197. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 199. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 201. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 205. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 206. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 221. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 222. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 223. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 225. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 229. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 231. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 233. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 237. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 247. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 248. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 249. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 253. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 255. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 256. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 257. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 258. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 261. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 262. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 269. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 270. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 278. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 280. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 282. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 286. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 287. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 288. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 289. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 290. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 293. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 294. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 295. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 296. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 297. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 298. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 302. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 303. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 309. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 310. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 311. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 318. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 319. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 323. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 325. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 326. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 327. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTIONS, 2018-2030 (USD MILLION)
TABLE 328. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 329. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
TABLE 330. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 331. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 332. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 333. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 334. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MIL

Companies Mentioned

The companies profiled in this Cephalosporin Drugs market report include:
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Viatris Inc.
  • Dr. Reddy’s Laboratories Ltd
  • Sun Pharmaceutical Industries Ltd
  • Lupin Limited
  • Cipla Limited
  • Sanofi S.A.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 12.95 Billion
Forecasted Market Value ( USD ) by 2030 $ 17.87 Billion
Compound Annual Growth Rate6.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cephalosporin Market Report by Generation, Route of Administration, Application, and Region ?2025-2033 - Product Image

Cephalosporin Market Report by Generation, Route of Administration, Application, and Region ?2025-2033

  • Report
  • 144 Pages
  • Global
From
Cephalosporin Drugs - Global Strategic Business Report - Product Image

Cephalosporin Drugs - Global Strategic Business Report

  • Report
  • 398 Pages
  • Global
From
Cephalosporin Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Cephalosporin Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Cephalosporin Market Report 2025 - Product Image

Cephalosporin Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Beta Lactam & Beta Lactamase Inhibitors Market by Drug Class, Route of Administration, Patient Type, Application, End User - Global Forecast to 2030 - Product Image

Beta Lactam & Beta Lactamase Inhibitors Market by Drug Class, Route of Administration, Patient Type, Application, End User - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From

About the Market

Cephalosporins are a class of antibiotics used to treat a wide range of bacterial infections. They are derived from the fungus Cephalosporium and are closely related to penicillin. Cephalosporins are divided into four generations, each generation having a broader spectrum of activity than the previous one. They are used to treat infections of the respiratory tract, urinary tract, skin, and soft tissue. Cephalosporins are also used to treat some sexually transmitted diseases, such as gonorrhea. Cephalosporins are widely used in both human and veterinary medicine. They are available in a variety of formulations, including tablets, capsules, suspensions, and injections. Cephalosporins are generally well tolerated, with few side effects. Some companies in the Cephalosporins market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and AstraZeneca. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.